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Abstract: We report a novel approach to the classical natural
product quinine that is based on two stereoselective key steps,
namely a C@H activation and an aldol reaction, to unite the two
heterocyclic moieties of the target molecule. This straightfor-
ward and flexible strategy enables a concise synthesis of natural
(@)-quinine, the first synthesis of unnatural (+)-quinine, and
also provides access to unprecedented C3-aryl analogues,
which were prepared in only six steps. We additionally
demonstrate that these structural analogues exhibit improved
antimalarial activity compared with (@)-quinine both in vitro
and in mice infected with Plasmodium berghei.
Among the many natural products described throughout the
chemical literature, quinine has undoubtedly one of the most
vivid and colorful histories. For over a century, this cinchona
alkaloid has attracted the attention of many researchers.[1] Its
potent antimalarial activity, especially against resistant
strains,[2] along with its privileged role in catalysis,[3] have
rendered it a highly coveted target. The first (formal)
synthesis of the alkaloid, widely regarded as a milestone in
total synthesis, was achieved by Woodward and Doering in
1944 and was heralded in the popular media.[4, 5] Taken
together, virtually all of the successful approaches to this
natural product share as a common trait (Figure 1a) the late-
stage construction of the quinuclidine moiety, namely through
a C8@N1 disconnection.[6] Despite the apparent structural
simplicity of quinine, the first enantioselective synthesis was
reported by Stork and co-workers as late as 2001,[7] with
a longest linear sequence of 14 steps and featuring an
innovative C6@N1 disconnection (Figure 1b). Notably, no
reported synthesis demonstrated the introduction of struc-
tural diversity at the C3 position although there are studies
that suggest that this site can modulate antimalarial activity.[8]
Furthermore, to the best of our knowledge, there are no
reports on either the synthesis or the biological activity of the
unnatural enantiomer (+)-quinine. Indeed, this enantiomer is
conspicuously absent throughout the vast literature of orga-
nocatalysis, where the diastereoisomeric analogue quinidine
is typically employed as a “pseudo”-enantiomer.
Figure 1. a,b) An overview of previous retrosynthetic approaches to
quinine (1) and c) our synthetic plan. For a comprehensive review on
prior syntheses, see Ref. [1a–d].
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Herein we report a straightforward and flexible strategy
enabling the concise stereoselective synthesis of both enan-
tiomers of quinine that is based on a selective C(sp3)@H
activation step and a novel C8@C9 disconnection through an
aldol addition. Furthermore, we disclose a short route
towards novel C3-aryl analogues and their in vivo biological
evaluation, revealing significantly enhanced antimalarial
activity.
Our synthetic plan predicated on the use of a preformed
quinuclidineA bearing a C7 (quinine numbering) substituent
X (Figure 1c). This substituent should simultaneously
1) embody the directing group to guide our planned C(sp3)@
H activation step while also 2) serving as a masked ketone to
facilitate the aldol event and ultimately 3) being amenable to
removal as a redundant functionality at the end of the
synthesis.
We chose the picolinamide directing group pioneered by
Daugulis and co-workers for the C(sp3)@H activation reac-
tion.[9, 10] This moiety was readily introduced in a coupling
reaction using commercially available 3-aminoquinuclidine
(2 ; Scheme 1).[11] From intermediate 3, we found that C(sp3)@
H arylation using palladium catalysis[12] can be achieved with
complete regio- and diastereocontrol. The observed selectiv-
ity is likely the result of the preferential formation of a five-
membered palladacyclic intermediate, combined with preclu-
sion of C(sp3)@H activation at C8 owing the inductive effect
of the adjacent nitrogen atom. Although direct C(sp3)@H
vinylation and alkenylation eluded our efforts despite exten-
sive investigation,[13] we established the C(sp3)@H arylation to
be a general transformation, as shown in Scheme 1.
Thus arenes bearing electron-donating (Me, OMe) as well
as electron-withdrawing groups (CF3, Cl, CO2Me, NO2) could
be efficiently appended to 3. Notably, 4-chloroiodobenzene
proved to be a suitable partner for the reaction and was
converted without affecting the chloride moiety, and esters
were also well-tolerated. ortho-Substituted arenes were
introduced, albeit in lower yield. The successful reaction
with a complex estradiol derivative is particularly noteworthy
(4j).
The availability of intermediate 4c in enantiomerically
pure (@)-form (starting from (@)-2) enabled a route towards
the natural product (Scheme 2). This was accomplished by
ruthenium-catalyzed oxidative degradation of the anisole
moiety to a carboxylic acid,[14] which was isolated as
zwitterion 5. Formation of Weinreb amide 6 was accom-
plished by a HATU-mediated coupling, and subsequent
reduction with DIBAL-H afforded the masked aldehyde
7.[15] It is noteworthy that no epimerization at the a-position
to the aldehydic carbon atom was observed during this
transformation, likely a fortuitous consequence of hemiami-
nal formation.
The desired vinyl moiety was then completed by Wittig
olefination to afford alkenyl-quinuclidine 8 (Scheme 2).[16]We
now sought to remove the directing group and set the stage
for an aldol-type reaction to introduce the quinoline portion
of the natural product. Having served its purpose, the
picolinamide moiety was removed under reducing conditions,
affording free amine 9.[17] After extensive experimentation,
we found that oxidation of this free amine to the correspond-
ing ketone using IBX led to the desired building block 10
(Scheme 2).[18] The amine-to-ketone functional group inter-
conversion is seldom utilized in total synthesis although
several methods have been reported.[19] In this case, proto-
nation of the nucleophilic quinuclidine nitrogen atom with
pTsOH as an additive proved to be crucial to achieve
oxidation in good yield. In the absence of the acid additive,
competing fragmentation of the bicyclic framework took
place.
Scheme 1. Scope of the divergent C(sp3)@H arylation on quinuclidine
3. Reagents and conditions: (1) picolinic acid, CDI, DMF, RT, 16 h;
(2) ArI, Pd(OAc)2, Ag2CO3, DMF, 100 8C, 16 h. * A 1:1 mixture of
diastereomers starting from (:)-3.
Scheme 2. Conversion of arylated (@)-4c into quinuclidone building
block 10. Reagents and conditions: (3) RuCl3, NaIO4, H2O, EtOAc,
CH3CN, RT, 18 h; (4) HATU, MeNHOMe·HCl, Et3N, DMF, RT, 18 h;
(5) DIBAL-H, DCM, @78 8C, 1.5 h; (6) Ph3PMeBr, LiHMDS, DMSO,
THF, @78 8C; (7) Zn, HCl, Zn(OTf)2, H2O, RT, 1.5 h; (8) IBX, pTsOH,
CH3CN, 70 8C, 2 h.
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With ketone 10 in hand, the stage was set for the aldol
reaction with 6-methoxyquinoline-4-carbaldehyde 12. We
noted that an early attempt toward the synthesis of quinine
by an aldol addition between an unsubstituted quinuclidinone
and benzaldehyde was previously reported by Stotter and co-
workers more than 30 years ago.[20] In that study, preliminary
experiments with 3-quinuclidone and benzaldehyde as model
substrates revealed rapid epimerization (i.e., configurational
instability) of the aldol product. Although the authors
overcame this undesired isomerization through in situ reduc-
tion of the newly formed addition product, this approach to
the synthesis of quinine ultimately proved unsuccessful. More
recently, Williams and co-workers made similar observations
in the course of their synthesis of 7-hydroxyquinine.[21]
In our initial studies, we prepared racemic aryl-substituted
quinuclidone 11c (see the Supporting Information for details)
as a readily available model substrate. As shown in Sche-
me 3a, the aldol reaction of 11 with aldehyde 12 proceeded in
very good yield. In analogy to the studies of Stotter,[20] the
productB underwent rapid epimerization to the undesired C8
diastereomer upon attempted purification. Recognizing that
the acidity at C8 (marked * in Scheme 3a) must be rapidly
curtailed following the aldol reaction, we eventually found
that epimerization could be suppressed by in situ treatment of
the nascent aldol addition product with Ti(OiPr)3Cl followed
by conversion of the ketone functional group into a sulfonyl-
hydrazone in a one-pot operation. This sequence of oper-
ations enabled the isolation of 13 in 86% yield with a high
level of diastereoselectivity (> 16:1 d.r., relative configura-
tion assigned by X-ray structure analysis after TBS protec-
tion).[22]
Applying these same aldol reaction conditions to vinyl-
substituted quinine precursor 10 proved similarly successful;
the desired tosylhydrazone was obtained in high yield and
excellent diastereoselectivity (see the Supporting Informa-
tion), leaving the removal of this functional group as the final
remaining step. Despite its apparent simplicity, this proved to
be a very challenging endeavor. A plethora of common
reductants (NaBH4, DIBAL-H, NaBH3CN, among others)
led either to no reaction or to undesired side products.
Various modifications of the Wolff–Kishner reduction (such
as Myers or Cram)[23] were also investigated but failed to
afford the desired product, while alternative approaches to
trap the configurationally labile aldol product (e.g., as
a dithiane or diol) likewise proved unsuccessful. Consider-
ations of molecular models of hydrazone 13 revealed severe
steric congestion around the hydrazone C=N carbon atom
and suggested that this might be responsible for its exper-
imentally observed slow reduction and sluggish sulfonyl
elimination. We eventually found that the critical choice of
the less sterically demanding methanesulfonyl-hydrazone 14
(Scheme 3b), along with the more reactive reducing system
LiAlH4/MeOH (presumably generating trimethoxyaluminum
hydride) was capable of finally delivering (@)-quinine (1) in
53% yield (Scheme 3b). Our synthesis of this natural product
thus stands at ten steps from (@)-2 and 5.4% overall yield.
The flexibility of this synthetic approach allowed us to
apply an analogous synthetic sequence to prepare the
unnatural enantiomer (+)-quinine. To the best of our knowl-
edge, no study exists on the biological activity of the unnatural
antipode of this natural product.[24] Furthermore, when
applied to the C@H activation products (:)-4b and (:)-4c,
the synthetic sequence outlined herein resulted in two novel
analogues of quinine, (:)-15b and (:)-15c, in only four
additional steps (Table 1; for details, see the Supporting
Information). All of these compounds were tested for
antimalarial activity in vitro (see the Supporting Information,
Scheme 3. a) Model studies towards a stereoselective aldol reaction.
b) Endgame for the total synthesis of (@)-quinine. Reagents and
conditions: (9) LiHMDS, THF, @78 8C, 1 h, then aldehyde 12, then
Ti(OiPr)3Cl, MsNHNH2, RT, 3 h; (10) LiAlH4, MeOH, THF, RT, 10 min.
Table 1: In vivo activity of the racemic aryl analogues (:)-15b and (:)-
15c and (@)-quinine hydrochloride as a reference against P. berghei in
mice.
Substance Dose
[mg/kg]
Parasitemia
reduction [%][a]
Survival[b]
[days]
(@)-quinine hydrochloride 30 42 euthanized
100 80 7:0
(:)-15b[c] 30 98 8:1
100 99 21:7
(:)-15c[c] 30 0 euthanized
100 98 7:1
[a] Blood for parasitemia determination was collected on day 3 (72 h
after infection). [b] Mean survival time in days : standard deviation.
Mice with a parasitemia reduction <50% were euthanized on day 3
post-infection in order to prevent death, otherwise occurring on day 6.
[c] Purity of >99% determined by HPLC analysis.
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Table S1). The activity of (+)-quinine against Plasmodium
falciparum (P. falciparum) is slightly lower than that of (@)-
quinine whereas the novel C3-aryl analogues (:)-15b and
(:)-15c showed improved activity. Based on these results,
in vivo experiments using the aryl analogues on mice infected
with Plasmodium berghei (P. berghei) were performed
(Table 1).
The compounds were orally administered in a single dose
24 hours after infection and subsequently both the para-
sitemia after 3 days and the survival time were recorded. The
CF3-aryl analogue (:)-15b exhibited high antimalarial activ-
ity in both doses tested and also significantly increased the
survival time of the infected mice whereas (@)-quinine
exhibited only moderate activity at an oral dose of
100 mgkg@1. Remarkably, single-dose administration of
100 mgkg@1 of (:)-15b reduced the amount of parasitized
red blood cells to only 1%, and therefore prolonged the
average lifespan of the mice to 21 days, compared to 7 days
for (@)-quinine. Based on these results, replacement of the
vinyl group with a more lipophilic aryl moiety seems to
increase the efficacy of the drug.
In summary, we have presented a flexible and concise
approach to quinine that begins from commercially available
3-aminoquinuclidine and makes use of the lone amino
stereocenter for the introduction of all necessary function-
alities of the natural product with excellent regio- and
stereoselectivity. This enabled the synthesis of both natural
(@)- and unnatural (+)-quinine as well as two analogues
bearing aromatic groups at the C3 position.[25] The latter are
available in only six synthetic steps from aminoquinuclidine
and, given their significantly enhanced antimalarial activity
in vitro and in vivo, imply potential therapeutic applications
for the chemistry presented herein.
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